Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-16T21:13:16.767Z Has data issue: false hasContentIssue false
  • English
  • Français

5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine

A SPET study using the novel 5-HT2A ligand 1231-5-1-R-91150

Published online by Cambridge University Press:  03 January 2018

Michael J. Travis ,
Geraldo F. Busatto ,
Lyn S. Pilowsky ,
Rachel Mulligan ,
Paul D. Acton ,
Sveto Gacinovic ,
John Mertens ,
Dirk Terrière ,
Durval C. Costa  and
Peter J. Ell
...Show all authors
Michael J. Travis
Affiliation:
Institute of Psychiatry, London
Geraldo F. Busatto
Affiliation:
Institute of Psychiatry, London
Lyn S. Pilowsky
Affiliation:
Institute of Psychiatry, London
Rachel Mulligan
Affiliation:
Institute of Nuclear Medicine, London
Paul D. Acton
Affiliation:
Institute of Nuclear Medicine, London
Sveto Gacinovic
Affiliation:
Institute of Nuclear Medicine, London
John Mertens
Affiliation:
Biochem, Eng, VVB Cyclotron, Brussels, Belgium
Dirk Terrière
Affiliation:
Biochem, Eng, VVB Cyclotron, Brussels, Belgium
Durval C. Costa
Affiliation:
Institute of Nuclear Medicine, London
Peter J. Ell
Affiliation:
Institute of Nuclear Medicine, London
Robert W. Kerwin
Affiliation:
Institute of Psychiatry, London
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

5-HT2A receptor antagonism may be crucial to the action of atypical antipsychotics. Previous work has related 5-HT2A receptor blockade to clinical efficacy and protection from extrapyramidal side-effects.

Method

We developed a SPET imaging protocol for assessing 5-HT2A receptor binding using the selective ligand 1231-5-1-R91150. Six healthy volunteers, five clozapine- and five risperidone-treated subjects with DSM–IV schizophrenia were studied. Multi-slice SPET was performed on each subject.

Results

Cortex: cerebellum ratios were significantly lower in both clozapine-and risperidone-treated subjects compared with the healthy volunteers in all cortical regions. There was no difference in occupancy between the two drug-treated groups. No correlation was found between the percentage change in the Global Assessment Scale (GAS) and 5-HT2A receptor binding indices in the drug-treated groups.

Conclusions

Clozapine and risperidone potently block 5-HT2A receptors in vivo. The lack of relationship between receptor binding indices and change in GAS suggests that 5-HT2A receptor blockade may be unrelated to clinical improvement. Future studies will substantiate this finding by studying 5-HT2A receptor binding in large groups of patients treated with both typical and novel atypical antipsychotics.

Type
Papers
Information
The British Journal of Psychiatry , Volume 173 , Issue 3 , September 1998 , pp. 236 - 241
Copyright
Copyright © 1998 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andreasen, N. C. (1989) The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. British Journal of Psychiatry, 155, (suppl. 7). 49–58.Google Scholar
Arranz, M. Collier, D. Sodhi, M. et al (1995) Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet, 346, 281–282.Google Scholar
Barnes, T. R. E. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676.Google Scholar
Busatto, G. F. Pilowsky, L. S. Costa, D. C. et al (1997) Initial evaluation of 123-1-5-1-R91150. a selective 5-HT2A ligand for single photon emission tomography (SPET), in healthy human subjects. European Journal of Nuclear Medicine, 24, 119–124.Google Scholar
Busatto, G. F. & Kerwin, R. W. (1997) Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. Journal of Psychopharmacology 11, 3–12.Google Scholar
Curtis, V. A. Wright, P. Reveley, A. et al (1995) Effect of clozapine on d-fenfluramine evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. British Journal of Psychiatry, 166, 642–664.CrossRefGoogle ScholarPubMed
Ebmeier, K. P. Dougall, N. J. Austin, M. V. et al (1991) The split-dose technique for the study of psychological and pharmacological activation with the cerebral blood flow marker exametazime and single photon emission tomography: reproducibility and rater reliability. International Journal of Methods in Psychiatric Research, 1, 27–38.Google Scholar
Endicott, J. Spitzer, R. Fleiss, J. L. et al (1974) The Global Assessment Scale. Archives of General Psychiatry, 33, 766–771.Google Scholar
Endicott, J. & Spitzer, R. (1978) A diagnostic interview. The schedule for affective disorders and schizophrenia. Archives of General Psychiatry, 35, 837–844.CrossRefGoogle ScholarPubMed
Jenner, P. Sheehy, M. & Marsden, C. D. (1983) Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease. British Journal of Clinical Pharmacology, 15 (suppl. 2), 277s–289s.Google Scholar
Kahn, R. S. Davidson, M. Siever, L. et al (1993) Serotonin function and treatment response to clozapine in schizophrenic patients. American Journal of Psychiatry, 150, 1337–1342.Google Scholar
Kapur, S. & Remington, G. (1996) Serotonin– dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry, 153, 466–476.Google Scholar
Kay, S. R. Fiszbein, A. & Opler, L. A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.Google Scholar
Kerwin, R. W. (1994) The new atypical antipsychotics. British Journal of Psychiatry 164, 141–148.Google Scholar
Knable, M. B. Heinz, A. Raedler, T. et al (1997) Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Research, 75, 91–101.Google Scholar
Lane, R. D. Glazer, W. M. Hansen, T. E. et al (1985) Assessment of tardive dyskinesia using the abnormal involuntary movement scale. Journal of Nervous and Mental Disorders, 173, 353–357.Google Scholar
Meitzer, H. Y. (1989) Clinical studies on the mechanism of action of clozapine: the dopamine–serotonin hypothesis of schizophrenia. Psychopharmacology, 99 (suppl.), 18–27.Google Scholar
Mertens, J. Terrière, D. Sipido, V. et al (1994) Radiosynthesis of a new radioiodinated ligand for serotonin-5-HT2A-receptors, a promising tracer for γ-emission tomography. Journal of Labelled Compounds and Radiopharmaceuticals, 34, 795–806.CrossRefGoogle Scholar
Nyberg, S. Nakashima, Y. Nordström, A.-L. et al (1996) Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2A receptor occupancy studies and clinical response. British Journal of Psychiatry 168 (suppl. 29), 40–44.Google Scholar
Pazos, A. Probst, A. & Palacios, J. M. (1987) Serotonin receptors in the human brain. IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience, 21, 123–139.CrossRefGoogle ScholarPubMed
Peuskens, J. (1995) Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind parallel-group study versus haloperidol. British Journal of Psychiatry, 166, 712–726.CrossRefGoogle ScholarPubMed
Pilowsky, L. S. Costa, D. C. Ell, P. J. et al (1992) Clozapine, single photon emission tomography, and the D 2 dopamine receptor blockade hypothesis of schizophrenia, Lancet, 240, 199–202.CrossRefGoogle Scholar
Schotte, A. Janssen, P. F. Gommeren, W. et al (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124, 57–73.Google Scholar
Simpson, G. M. & Angus, J. W. S. (1970) A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica, 212 (suppl. 44), 11–19.CrossRefGoogle ScholarPubMed
Trichard, C. Paillière-Martinot, M. L. Attar-Levy, D. et al (1998) Binding of antipsychotic drugs to cortical 5-HT2A receptors: A PET study of chlorpromazine, clozapine, and amisulpiride in schizophrenic patients. American Journal of Psychiatry 155, 505–508.Google Scholar
Travis, M. J. (1997) Clozapine: A review. Journal of Serotonin Research, 4, 125–144.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.